文献速递妇科

子宫内膜癌研究进展:前妇科肿瘤组的贡献

Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group.
PubMed 文献 · Gynecol Oncol · 2020-02-01

本文回顾了妇科肿瘤组(GOG)四十余年在子宫内膜癌治疗领域的贡献。从细致的前瞻性手术病理分期研究开始,建立了低、中、高风险患者的统计模型,并以此指导治疗试验。化疗的作用得以确立,新型抗肿瘤药物经过广泛II期测试后纳入晚期子宫内膜癌的比较试验,多模式治疗持续展现前景,激素治疗及联合方案得到深入研究,生物制剂和现代影像技术正在积极研究中。GOG0210建立了具有详细临床和流行病学数据的标本库,有望加深对子宫内膜癌复发风险相关分子特征的理解。

要点

  • GOG的前瞻性手术病理分期研究为后续试验奠定基础。
  • 建立了低、中、高风险分组模型以指导治疗。
  • 化疗作用确立,新药经II期测试后纳入晚期比较试验。

核心结论

  • 妇科肿瘤组四十余年的研究推动了子宫内膜癌治疗的进步。
  • 手术病理分期研究为后续试验提供了平台。
  • GOG0210标本库有助于理解复发风险的分子特征。

研究设计与样本

  • 本文为综述,总结了妇科肿瘤组(GOG)在子宫内膜癌领域的研究历程。

主要发现

  • 建立了低、中、高风险患者的统计模型,指导治疗试验针对疾病扩散。
  • 化疗的作用得以明确,新型抗肿瘤药物经过广泛II期测试后纳入晚期子宫内膜癌比较试验。
  • 多模式治疗持续展现前景,激素治疗及联合方案得到深入研究。
  • 生物制剂和现代影像技术正在积极研究中。
  • GOG0210建立了具有详细临床和流行病学数据的临床标本库。

临床怎么用

  • 临床可依据低、中、高风险分组模型对子宫内膜癌患者进行分层治疗。
  • 化疗在子宫内膜癌治疗中具有明确作用。
  • 新型抗肿瘤药物和生物制剂可考虑用于晚期子宫内膜癌的试验性治疗。
  • 多模式治疗和激素联合治疗可用于特定患者。
  • GOG0210标本库可用于研究子宫内膜癌复发风险的分子特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For over forty years, the Gynecologic Oncology Group drove progress in treating endometrial cancer. The first decades of investigation began with a meticulous prospective, surgicopathologic staging study that was the platform for development of all subsequent trials. The resultant statistical model of low risk, intermediate risk, and high-risk groups of patients led to trials where therapeutic modalities were best targeted at disease spread. A clear role for chemotherapy was established. It was realized that greater advances might be achieved with the advent of newer anti-neoplastic agents and these agents were subjected to extensive phase II testing. These agents later were integrated into comparison trials for advanced endometrial cancer. Multimodality therapy continues to show promise. Hormonal therapy was thoroughly investigated and led to combination hormonal therapy trials. Newer agents, including biologics are under active study, as well as the potential contribution of modern imaging techniques. Finally, GOG0210 established a repository of clinical specimens with detailed clinical and epidemiologic data from patients with surgically staged endometrial carcinoma. This should provide for a much greater understanding of molecular characteristics associated with risk of endometrial cancer recurrence, clinical and histological characteristics, and epidemiologic factors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Miller DS, Randall ME, Filiaci V, et al. Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group. Gynecol Oncol. 2020. PMID: 32014330. doi:10.1016/j.ygyno.2020.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。